Revolution Medicines (RVMD)Director sold ~$271K

~$271K

Approx. value · 5,000 sh @ $54.14

20K

Holds after · shares reported

Traded

Oct 31, 2024

Filed

Nov 4, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 1, 2024Insider · 1 personInsiders: 2 sales (~$449K)
2. Oct 8, 2024InsiderDirector sold ~$250K of RVMD shares in the open market
3. Oct 11, 2024Insider · 4 peopleInsiders: 4 sales (~$4.8M)
4. Oct 14, 2024Insider · 1 personInsiders: 2 sales (~$825K)
5. Oct 31, 2024 · this disclosureInsiderDirector sold ~$271K of RVMD shares in the open market

What came next

1. Nov 1, 2024Insider · 1 personInsiders: 3 sales (~$1.1M)
2. Nov 4, 2024InsiderDirector sold ~$2.83M of RVMD shares in the open market
3. Nov 6, 2024InsiderOfficer sold ~$360K of RVMD shares in the open market
4. Nov 13, 2024Insider · 1 personInsiders: 2 sales (~$978K)
5. Nov 15, 2024InsiderOfficer sold ~$141K of RVMD shares in the open market
6. Dec 5, 2024Insider · 1 personInsiders: 2 purchases (~$60.0M)
7. Dec 16, 2024Insider · 5 peopleInsiders: 5 sales (~$1.1M)
8. Jan 21, 2025InsiderOfficer sold ~$97K of RVMD shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Revolution Medicines

For Revolution Medicines, OQRO holds 13 insider filings (SEC Form 4 or Form 144), 20 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RVMD page.

Other recent filings by Sushil Patel, Director

• SEC Form 4 at Replimune Group (REPL)May 23, 2025
• SEC Form 4 at Replimune Group (REPL)Dec 19, 2024

The full history of Sushil Patel, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Revolution Medicines

• USAspending.gov award recordOct 6, 2026
• SEC Form 4Oct 1, 2026
• SEC Form 4Oct 1, 2026
• SEC Form 4Oct 1, 2026
• SEC Form 4Oct 1, 2026
• SEC Form 4Oct 1, 2026

Everything OQRO holds on this company is on its RVMD page.